NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
3.400
+0.020 (0.59%)
At close: Jun 2, 2026, 4:00 PM EDT
3.300
-0.100 (-2.94%)
Pre-market: Jun 3, 2026, 5:38 AM EDT
NextCure Employees
NextCure had 40 employees as of December 31, 2025. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
n/a
Profits / Employee
-$1,366,600
Market Cap
12.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 40 | -3 | -6.98% |
| Dec 31, 2024 | 43 | -39 | -47.56% |
| Dec 31, 2023 | 82 | -17 | -17.17% |
| Dec 31, 2022 | 99 | 12 | 13.79% |
| Dec 31, 2021 | 87 | -3 | -3.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| Theriva Biologics | 16 |
| CalciMedica | 16 |
| Kiora Pharmaceuticals | 13 |
| BioVie | 13 |
| Intensity Therapeutics | 7 |
| Immuron | 7 |
| Phio Pharmaceuticals | 6 |
NXTC News
- 22 hours ago - NextCure Transcript: KOL event - Transcripts
- 22 hours ago - NextCure Press release: KOL event - Filings
- 22 hours ago - NextCure Slides: KOL event - Filings
- 1 day ago - NextCure share weakness overdone, says Lucid Capital - TheFly
- 1 day ago - NextCure presents Phase 1 data for SIM0505 in gynecologic cancers - TheFly
- 1 day ago - NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - GlobeNewsWire
- 22 days ago - NextCure initiated with a Buy at Lucid Capital - TheFly
- 26 days ago - NextCure reports Q1 EPS ($1.87), consensus ($2.03) - TheFly